Abstract
Patients with epilepsy require long-term treatment with antiepileptic drugs (AEDs), and in female patients the management of epilepsy before, during, and after pregnancy is critical. Pregnancy is associated with pharmacokinetic changes, including increased volume of distribution, elevated renal clearance, and induction of drug-metabolizing enzymes (cytochrome p450 [CYP] family and uridine diphosphate glucuronosyltransferase [UGTs]). For example, the concentrations of lamotrigine, which is metabolized in the liver by UGTs, and levetiracetam, which is primarily eliminated by renal excretion, can decrease by 40% to 80% during pregnancy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
